How is the pharmaceutical industry reacting to the FDA’s surprising approval of a controversial Alzheimer’s drug, and what do they make of its $56,000 price tag?This is the last episode in our weeklong series examining the potentially sweeping consequences this drug, known as aducanumab, could have on millions of patients’ lives and billions of dollars in health care spending.Guest:Luke Timmerman, Journalist/Founder, Timmerman ReportExplore the full series and additional resources: https://tradeoffs.org/aducanumabRead a transcript of this episode: https://tradeoffs.org/2021/06/25/the-aducanumab-aftermath-the-industry/Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: bit.ly/tradeoffsnewsletterSupport this type of journalism today, with a gift: https://tradeoffs.org/donateFollow us on Twitter: https://twitter.com/tradeoffspod Hosted on Acast. See acast.com/privacy for more information.

Ver todos los episodios